Corrigendum: Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction

Front Cardiovasc Med. 2022 Feb 23:9:840102. doi: 10.3389/fcvm.2022.840102. eCollection 2022.

¹ Cardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theater Command, Shenyang, China.
² Department of Cardiology, Liaoning Provincial People's Hospital, Shenyang, China.
³ Department of Cardiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
⁴ Department of Cardiology, General Hospital of the Strategic Support Force of the Chinese People's Liberation Army, Beijing, China.
⁵ Department of Cardiology First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
⁶ Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States.
⁷ Icahn School of Medicine at Mount Sinai, Mount Sinai Heart and the Cardiovascular Research Foundation, New York, NY, United States.

Abstract

[This corrects the article DOI: 10.3389/fcvm.2021.747511.].

Keywords: S100A12; ST-segment elevation myocardial infarction; cardiovascular disease(s); diagnosis; prognosis.